Drs. Ben Solomon, Leora Horn, & Jack West compare the clinical data with the third generation EGFR TKIs so active in acquired resistance and consider whether there are significant differences between them.
Are There Clinically Significant Differences Among the First and Second Generation EGFR TKIs (Iressa, Tarceva, Gilotrif)?
Drs. Ben Solomon, Leora Horn, & Jack West review whether the data and clinical experience suggest any clinically significant differences among the first and second generation EGFR TKIs (Iressa, Tarceva, Gilotrif/Giotrif).
What Are the Treatment Choices for EGFR Mutation-Positive Acquired Resistance in Patients Without a T790M Mutation?
Drs. Ben Solomon, Leora Horn, & Jack West consider the range of treatment options for patients with an EGFR mutation and acquired resistance that does not harbor a T790M mutation.
Should Third Generation EGFR Inhibitors Be Used Before First Generation EGFR TKIs or After Progression?
Drs. Leora Horn, Ben Solomon, & Jack West consider whether third generation EGFR TKIs, so active in patients with acquired resistance, might be best used prior to development of acquired resistance.
Dr. Greg Riely, medical oncologist from MSKCC, discusses the controversial question of whether patients should continue on an oral EGFR tyrosine kinase inhibitor after progression.
MSKCC medical oncologist Dr. Greg Riely explains the growing value of a repeat biopsy after the development of acquired resistance in patients with an EGFR mutation.
Medical oncologist Dr. Greg Riely, MSKCC, summarizes the development of acquired resistance after a good initial response to EGFR inhibitor therapy and the clinical patterns of progression commonly seen.
Dr. Geoffrey Oxnard on Managing Acquired Resistance to EGFR Inhibitor Therapy (and Probably Crizotinib, Too)
Dr. Geoffrey Oxnard, Dana Farber Cancer Institute, describes a wide range of options for best managing patients with advanced NSCLC who experience acquired resistance, the progression of cancer after a good initial response to a targeted therapy.
Heterogeneity in Population of NSCLC Patients with Acquired Resistance to EGFR Inhibitors: T790M is Key Predictor
Over the past several years, probably the biggest development in the field of NSCLC has been the recognition of the importance of molecularly-defined subgroups that help define the clinical patterns of how patients are likely to do with various treatments. We've seen this clearly illustrated with EGFR mutations vs.